AstraZeneca ups EPS guidance on double-digit Q1 profit growth
This article was originally published in Scrip
Executive Summary
AstraZeneca has raised its full-year EPS guidance to $6.05-6.35 after its first-quarter net profits leapt by 30% to $2.8 billion on a reported basis.